BAM
TXMD icon

Belpointe Asset Management’s TherapeuticsMD TXMD Stock Holding History

Belpointe Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$1.12K – 3853
2022
Q4 		$1.12K Buy
+200
New +$1.18K ﹤0.01% 3416

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Belpointe Asset Management's TXMD Position: Q1 2023 in Review

Belpointe Asset Management sold out of TherapeuticsMD (TXMD) in Q1 2023, closing a stake of 200 shares — an estimated $1.12K sold.

Belpointe Asset Management first reported a position in TXMD in Q4 2022 and held it in 1 quarter. The position peaked at $1.12K in Q4 2022. 41 funds tracked by Wall St. Rank hold TXMD as of Q1 2023.

  • Belpointe Asset Management reported no remaining TherapeuticsMD position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 200 TherapeuticsMD shares in Q1 2023, an estimated $1.12K.
  • Belpointe Asset Management first reported a position in TherapeuticsMD in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's TherapeuticsMD position peaked at $1.12K in Q4 2022.
  • 41 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.